This ELISA kit provides quantitative measurement of PCSK9 (proprotein convertase subtilisin/kexin type 9) in human samples, supporting research into lipid metabolism and cardiovascular risk. Because circulating PCSK9 levels vary substantially with statin therapy, fasting status, and metabolic syndrome severity, accurate quantification across these conditions demands a well-calibrated assay.
Detection Range: The 0.45–30 ng/mL range falls below typical human plasma PCSK9 concentrations (approximately 30–3,000 ng/mL), meaning most serum and plasma samples will require dilution. This is advantageous, as it allows researchers to use a single dilution factor that accommodates both baseline and post-treatment samples, including the marked reductions seen with PCSK9 inhibitor therapy.
Sensitivity: The 0.225 ng/mL sensitivity enables detection of PCSK9 in tissue homogenates and conditioned media from hepatocyte cultures, where local concentrations are significantly lower than circulating levels.
Sample Compatibility: Validation across serum, plasma, and tissue homogenates allows researchers to correlate circulating PCSK9 with hepatic expression directly, linking systemic lipid regulation to tissue-level biology within a single experimental framework.
Assay Efficiency: The 1–5 hour protocol and 50–100 µL sample volume accommodate longitudinal clinical cohort studies where serial blood draws yield limited volumes and high sample throughput is essential.
This kit is well suited for studies of familial hypercholesterolemia, statin response monitoring, and PCSK9 inhibitor pharmacodynamics.